Transdermal Theophylline Patch for Continuous Remyelination Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for demyelinating diseases, such as multiple sclerosis and Charcot Marie Tooth disease, require inconvenient daily injections and lack effective, convenient methods for achieving and maintaining systemic exposure to HDAC1/2 activators like theophylline, which are necessary for remyelination.

Innovation Solution

A transdermal patch containing aminophylline or theophylline as the sole active ingredient, formulated with a matrix layer comprising a matrix polymer, permeation enhancer, and plasticizer, allowing for continuous delivery of therapeutically effective plasma levels of theophylline over several days.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If daily intraperitoneal injections of theophylline are used to achieve remyelination, then therapeutic effect is improved, but patient convenience and adherence deteriorate

Engineering Contradiction:

Improvetherapeutic effectVSAvoidpatient convenience

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent replaces the mechanical injection system (intraperitoneal injections) with a transdermal delivery system (patch). The patch utilizes skin permeation to deliver theophylline continuously, eliminating the need for daily injections and improving patient convenience while maintaining therapeutic effectiveness.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces a transdermal patch as an intermediary delivery vehicle between the theophylline drug and the patient's body. The patch serves as a mediator that enables continuous, convenient delivery of theophylline through the skin, resolving the contradiction between therapeutic reliability and patient convenience.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If high daily doses of theophylline are administered to achieve significant remyelination, then therapeutic outcome is improved, but treatment complexity and burden increase

Engineering Contradiction:

Improveremyelination effectivenessVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent implements continuous delivery of theophylline through the transdermal patch over extended periods (up to 7 days or longer). This continuous action maintains steady plasma concentrations, ensuring consistent remyelination effectiveness while simplifying the treatment regimen compared to daily dosing.

Inventive Principle:

Principle #20Continuity of useful action

Solution Approach 2:

The patent employs a dynamic delivery system where the patch rate-controlling membrane regulates theophylline release to maintain optimal plasma concentrations. This dynamic control ensures therapeutic effectiveness while reducing treatment complexity by eliminating the need for daily dose adjustments.

Inventive Principle:

Principle #15Dynamics

3Ease of operation

If transdermal delivery of theophylline is implemented, then patient convenience is improved, but achieving and maintaining effective plasma levels becomes more difficult

Engineering Contradiction:

Improvepatient convenienceVSAvoidplasma level control

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent modifies the delivery parameters by using a rate-controlling membrane with specific permeability characteristics. This parameter change enables the patch to deliver theophylline at a controlled rate that maintains effective plasma concentrations while ensuring patient convenience through continuous, painless delivery.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The rate-controlling membrane acts as an intermediary barrier that regulates theophylline transfer from the patch to the skin. This intermediary structure ensures reliable plasma level control by mediating the drug release rate, simultaneously achieving patient convenience through simplified application.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The transdermal patch achieves steady-state plasma concentrations of 0.3 to 2.5 μg/ml of theophylline, facilitating remyelination and providing a convenient, chronic therapy option for demyelinating diseases without the need for frequent injections.

Implementation Method 1

Methodology Applied

Scientific EffectTransdermal delivery: Permeation

Data Source

PatentUS20260069551A1Patch for treating demyelinating diseases

Publication Date: 2026.03.12 JOHANNES GUTENBERG UNIV

AI summary

A pharmaceutical composition in the form of a transdermal patch comprising aminophylline or theophylline for use in the treatment or prevention of a hypomyelinating or a demyelinating disease or condition or a lesion of the peripheral or central nervous system where demyelination occurs. The patch may comprise a matrix layer comprising a matrix polymer, an active ingredient and a permeation enhancer.